Literature DB >> 9713951

Pulmonary atresia with ventricular septal defect: a case for central venous pressure and oxygen saturation monitoring.

B M Weiss1, P G Atanassoff, R Jenni, B Walder, E Wight.   

Abstract

A 21-year-old patient with pulmonary atresia and ventricular septal defect (PA-VSD) was admitted to the hospital for tubal ligation. Invasive arterial and central venous (CVP) pressure, pulse oximetric oxygen saturation (SpO2), and (from the tip of oximetric central venous catheter) central venous oxygen saturation (ScvO2) and oxygen extraction rate (ExO2) were continuously monitored. Heart rate (range: 68-75 beat/min), mean arterial pressure (80-90 mmHg), CVP (7-10 mmHg), SpO2 (79-90 percent), ScvO2 (57-70 percent), and ExO2 (21-30 percent) remained stable during epidural anesthesia and transvaginal sterilization. Following an overnight stay (peak SpO2 92 percent; peak ScvO2 71 percent; through ExO2 21 percent), the oxygen data returned to baseline on awakening (SpO2 < 80 percent, ScvO2 < 55 percent, ExO2 > 35 percent), and the patient was discharged. In PA-VSD, a single-outlet double-ventricle anomaly, CVP reflects the preload of systemic ventricle. As the mixed venous oxygen saturation cannot be defined, ScvO2 is the best available indicator of the whole body oxygen consumption. Continuous monitoring of CVP, ScvO2 and ExO2 in the superior vena cava may provide more insight into the response to anesthesia and surgery in patients with PA-VSD.

Entities:  

Mesh:

Year:  1998        PMID: 9713951      PMCID: PMC2578918     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  23 in total

1.  Epidural anesthesia in patients with palliated cyanotic congenital heart disease.

Authors:  R S Holzman; C D Nargozian; R Marnach; C O McMillan
Journal:  J Cardiothorac Vasc Anesth       Date:  1992-06       Impact factor: 2.628

2.  Does central venous oxygen saturation accurately reflect mixed venous oxygen saturation? Nothing is simple, unfortunately.

Authors:  J L Vincent
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

3.  Craniotomy in a patient with Eisenmenger's syndrome.

Authors:  M A Chaney
Journal:  Anesth Analg       Date:  1992-08       Impact factor: 5.108

4.  Successful pulmonary resection after spontaneous hemopneumothorax in the Eisenmenger syndrome.

Authors:  J Au; S P Cusack; W S Walker
Journal:  Thorax       Date:  1991-07       Impact factor: 9.139

5.  Pheochromocytoma in a patient with Eisenmenger's complex.

Authors:  T W Rutter; V Mullin
Journal:  Anesth Analg       Date:  1991-10       Impact factor: 5.108

6.  Epidural anesthesia for a cesarean section in a patient with pulmonary atresia and ventricular septal defect.

Authors:  P G Atanassoff; E R Schmid; R Jenni; U Arbenz; E Alon; T Pasch
Journal:  J Clin Anesth       Date:  1991 Sep-Oct       Impact factor: 9.452

7.  Superior vena caval and mixed venous oxyhemoglobin saturations in children recovering from open heart surgery.

Authors:  J Räsänen; K Peltola; M Leijala
Journal:  J Clin Monit       Date:  1992-01

8.  Systemic oxygen transport in patients with congenital heart disease.

Authors:  W Berman; S C Wood; S M Yabek; T Dillon; R R Fripp; R Burstein
Journal:  Circulation       Date:  1987-02       Impact factor: 29.690

9.  Pulmonary atresia with ventricular septal defect: preoperative and postoperative responses to exercise.

Authors:  G Barber; G K Danielson; F J Puga; C T Heise; D J Driscoll
Journal:  J Am Coll Cardiol       Date:  1986-03       Impact factor: 24.094

10.  Laparoscopic tubal sterilization under local anesthesia in women with cyanotic heart disease.

Authors:  M C Snabes; A N Poindexter
Journal:  Obstet Gynecol       Date:  1991-09       Impact factor: 7.661

View more
  1 in total

1.  Anesthetic dilemma in planning bilateral cataract surgery for an infant associated with congenital cardiac anomaly.

Authors:  Devalina Goswami; Shwetha Seetharamaiah; Sraban Kumar Kedia; Bhagabat Kumar Nayak; Shiv Akshat
Journal:  Indian J Ophthalmol       Date:  2015-06       Impact factor: 1.848

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.